Higher Order Structure

与小分子药物不同，生物制剂是在生物系统中生产的，不仅具有初级，第二，第三和可能是第四纪结构。确定生物药物的高阶结构对于确保功效，稳定性和安全性至关重要。

NMRis perfectly suited to evaluate protein structures and to assess whether critical changes have occurred in a biotherapeutic drug during development and manufacturing. Because of its intrinsically high information content, NMR is proving to be a uniquely valuable tool for the评估HOS, reducing the number of techniques needed to characterize biotherapeutic drugs. Recent advances in data acquisition and analysis have ensured that it is now possible to study intact materials (including monoclonal antibodies) at natural abundance, under conditions that are physiologically relevant. The newMbioHOSsoftware offers a tool box of 1D and 2D method to evaluate higher order structure of biotherapeutic drugs. Additionally, the assessment of similarity between a biosimilar drug and its reference material is now fast and easy, allowing rapid pass / fail evaluations to be made.

FT-IRcontributes to the portfolio of orthogonal techniques for HOS analysis by giving insight into the secondary structure of proteins. The analysis is performed very quickly (~1 min/sample) and is characterized by a high tolerance against varying sample properties such as protein concentration, buffer components and excipients. These properties make the method an optimal tool to monitor the conformation of biopharmaceutical proteins during the development phase and for routine quality control.

This example application shows the IR spectra of an antibody at different temperatures (25-95° C). As indicated by the unchanged amide I band shape the protein maintains its native-sheet structure up to ~60° C. Further heating causes a decrease in intensity indicative of intramolecular-β-sheets unfolding